United States Ketamine Clinics Market Insights Forecasts to 2033

• The U.S. Ketamine Clinics Market Size was valued at USD 3.35 Billion in 2023.
• The Market is growing at a CAGR of 10.45% from 2023 to 2033
• The U.S. Ketamine Clinics Market Size is expected to reach USD 9.05 Billion by 2033

The United States Ketamine Clinics Market is anticipated to exceed USD 9.05 Billion by 2033, growing at a CAGR of 10.45% from 2023 to 2033. The growing incidence of treatment-resistant mental health conditions, increasing need for faster relief & personalized medicine, and shift towards alternative mental health treatments are driving the growth of the ketamine clinics market in the US.     

Market Overview

Ketamine clinics specialize in treating a range of mental health issues with the anesthetic medication ketamine. They are the medical facilities that provide services such as assessments, consultations, and treatments. Medical specialists such as nurses, psychologists, and psychiatrists work in the clinics. Ketamine clinics are gaining popularity as an alternative to conventional mental health treatments. The growing awareness of ketamine's potential to treat a variety of mental health conditions, including depression and post-traumatic stress disorder (PTSD), has drawn significant attention from investors and medical professionals and is largely responsible for this development. Additionally, KAT is being approved by medical professionals more and more, which is boosting clinic usage and referrals. Recent advancements indicate a shift toward the standardization of ketamine therapy in pain and mental health operations. Furthermore, the sector is witnessing an increase in innovation and research endeavors aimed at enhancing treatment strategies and expanding the range of illnesses amenable to ketamine-based therapy. The introduction of telehealth and digital therapies along with remote monitoring and consultations are accelerating patient convenience and accessibility.

Report Coverage

This research report categorizes the market for the US ketamine clinics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States ketamine clinics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US ketamine clinics market.

Driving Factors

The growing incidence of treatment-resistant mental health illnesses, including MDD, bipolar disorder, and PTSD surges the use of ketamine therapy alternative to conventional treatment options such as antidepressant medicines and psychotherapy. The growing need to provide relief more quickly than standard antidepressant drugs drives the market demand. Further, personalized medication in mental healthcare is propelling the market growth. In addition, the trend towards alternative mental health therapies owing to the surging demand for alternative innovative treatment approaches is augmenting the market expansion.

Restraining Factors

The adverse effects associated with ketamine therapy discourage patients from pursuing the treatment which may hamper the growth of the ketamine clinics market.

Market Segmentation

The United States Ketamine Clinics Market share is classified into treatment and therapy.

• The depression segment dominates the market with the largest market share during the forecast period.

The United States ketamine clinics market is segmented by treatment into depression, anxiety, PTSD, and others. Among these, the depression segment dominates the market with the largest market share during the forecast period. The CDC reports that between 2020 and 2021, the proportion of adults suffering from depression and anxiety rose from 36.4% to 41.5%. There is a growing ketamine clinics expansion to meet the increasing demand from clients in need of ketamine treatment for depression.

• The on-site therapy segment dominates the US ketamine clinics market during the forecast period.       

Based on the therapy, the U.S. ketamine clinics market is divided into on-site therapy and online therapy. Among these, the on-site therapy segment dominates the US ketamine clinics market during the forecast period. Onsite therapy offers a monitored and regulated environment to maximize treatment outcomes and ensure patient safety. The increasing popularity and the adoption of ketamine for mental health treatment are driving the market demand in the on-site therapy segment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the U.S. ketamine clinics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Better U, Inc.
• Ketamine Clinics Los Angeles
• Innerwell (KBS, Inc.)
• Klarity Clinic (Tebra Inc.)
• Klarisana Health
• Nue Life Health (NueCo Holdings, P.B.C.)
• Mindbloom, Inc.
• NY Ketamine Infusions
• Stella MSO LLC dba Field Trip Health
• Vitalitas Denver Ketamine Infusion Center
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In February 2024, Innerwell, a first-of-its-kind mental health platform, announced its expansion into in-network care with four major insurance partners in California, as well as two insurance partners in New York. This move extends the reach of Innerwell's range of innovative treatments, including traditional psychiatry and talk therapy alongside specialized modalities like ketamine treatment and EMDR.

• In November 2023, Mindbloom, the largest provider of psychedelic medicine, announced the launch of its Mastermind Series – the first expert-led psychedelic therapy program for overcoming heartbreak, burnout, and other mental health challenges.

• In January 2023, Nue Life Health (Nue Life), a next-generation mental wellness platform, announced the launch of Nue Network, a partnership program to expand access to the company’s HIPAA-compliant, comprehensive at-home ketamine treatment and integration therapy programs.

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United States Ketamine Clinics Market based on the below-mentioned segments:

US Ketamine Clinics Market, By Treatment

• Depression
• Anxiety
• PTSD
• Others

US Ketamine Clinics Market, By Therapy

• On-Site Therapy
• Online Therapy